Test Code RIDP Respiratory Infectious Disease Panel
Additional Codes
LAB2747
Methodology
Multiplexed Nucleic Acid Test using Filmarray
Instrument.
Includes detection of: Adenovirus, Coronavirus 229E,
Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43, Human
Metapneumovirus, Human Rhinovirus (1, 2, 3 and 4), Enterovirus,
Influenza A (H1-2009, H1, H3), Influenza B, Parainfluenza (1, 2, 3,
and 4), Respiratory Syncytial Virus, Bordetella pertussis, Bordetella parapertussis,
Chlamydophila pneumoniae, Mycoplasma pneumoniae and SARS-CoV-2 virus.
NOTE:
The clinical presentation of respiratory
infections overlap and are non-specific. Even though
viruses tend to peak at certain times of the year, epidemiology
data had proven that multiple organisms are present in the
community at the same time. Because specific individual
respiratory viral orders are not clinically useful, the individual
order will be replaced with the panel order per Board approved
policy. Please contact a Clinical Pathologist at 269-341-8897
with any questions.
Specimen Requirements
Specimen source is required.
Specimen Type: Nasopharyngeal
Container/Tube: Flocked nasopharyngeal swab
in VTM (Viral Transport Media).
Specimen Volume: Swab
Collection Instructions:
1. For detailed nasopharyngeal collection instructions, see
Nasopharyngeal Collection Procedure in the Resources section.
2. Place swab in M4 transport medium to ensure specimen
preservation.
3. Label tube with patient’s full name, date of birth,
date and time of collection, and source of specimen.
Specimen Transport Temperature
Refrigerate 3 days / Ambient 4 hours / Frozen 30 days
Reference Values
Normal result: Negative for viral nucleic acid
Abnormal result: Positive for viral nucleic acid
Day(s) Test Set Up
Monday through Sunday – 24/7
Test Classification and CPT Coding
CPT 0202U
Adenovirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus
NL63, Coronavirus OC43, Human Metapneumovirus, Human Rhinovirus (1,
2, 3 and 4), Enterovirus, Influenza A (H1-2009, H1, H3), Influenza
B, Parainfluenza (1, 2, 3, and 4), Respiratory Syncytial Virus.
Bordetella pertussis
Bordetella parapertussis
Chlamydophila pneumoniae
Mycoplasma pneumoniae.
Clinical Utility
FilmArray Respiratory Panel (RP) is a multiplexed nucleic acid
test intended for use with the FilmArray instrument for the
simultaneous qualitative detection and identification of multiple
respiratory viral and bacterial nucleic acids in nasopharyngeal
swabs (NPS) obtained from individuals suspected of respiratory
tract infections. The following organism types and subtypes are
identified using the FilmArray RP: Adenovirus, Coronavirus 229E,
Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43, Human
Metapneumovirus, Influenza A, Influenza A subtype H1, Influenza A
subtype H3, Influenza A subtype 2009 H1, Influenza B, Parainfluenza
Virus 1, Parainfluenza Virus 2, Parainfluenza Virus 3,
Parainfluenza Virus 4, Rhinovirus/Enterovirus, Respiratory
Syncytial Virus, Bordetella pertussis, Bordetella parapertussis
Chlamydophila pneumoniae, Mycoplasma pneumoniae and SARS-CoV-2 virus.
The detection and identification of specific viral
and bacterial nucleic acids from individuals exhibiting signs and
symptoms of a respiratory infection aids in the diagnosis of
respiratory infection if used in conjunction with other clinical
and epidemiological information. The results of this test should
not be used as the sole basis for diagnosis, treatment, or other
management decisions.
Negative results in the setting of a respiratory illness may be
due to infection with pathogens that are not detected by this test
or, lower respiratory tract infection that is not detected by a
nasopharyngeal swab specimen. Positive results do not rule out
co-infection with other organisms; the agent(s) detected by the
Film Array RP may not be the definite cause of disease. Additional
laboratory testing (e.g. bacterial and viral culture,
immunofluorescence, and radiography) may be necessary when
evaluating a patient with possible respiratory tract
infection.
The FilmArray RP assay for Coronavirus OC43 may cross-react with
some isolates of Coronavirus HKU1. A dual positive result may be
due to cross-reactivity or may indicate a co-infection.
Performance characteristics for influenza A were established
when influenza A/2009 H1N1, A/H1, and A/H3 were the predominant
influenza A viruses in circulation. Performance of detecting
influenza A may vary if other
influenza A strains are circulating or a novel influenza A virus
emerges. If infection with a novel influenza A virus
is suspected based on current clinical and epidemiological
screening criteria recommended by public health
authorities, specimens should be collected with appropriate
infection control precautions for novel virulent influenza viruses
and sent to state or local health departments for testing.